StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $30.78 | $30.89 | +0.36% | 0.1M |
| 05-12 | $30.66 | $31.54 | +2.87% | 0.1M |
| 05-13 | $31.54 | $32.62 | +3.42% | 0.1M |
| 05-14 | $32.97 | $31.27 | -5.16% | 0.1M |
| 05-15 | $30.64 | $30.14 | -1.63% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $925.00K |
Operating Income | $-103.33M | $-75.80M | $-52.00M | $-82.61M |
Net Income | $-90.35M | $-65.62M | $-22.02M | $-75.14M |
EPS (Diluted) | $-4.24 | $-3.11 | $-2.12 | $-4.28 |
Total Assets | $288.60M | $287.83M | $297.32M | $335.73M |
Total Liabilities | $23.72M | $22.29M | $24.06M | $25.36M |
Cash & Equivalents | $103.84M | $71.00M | $58.81M | $136.59M |
Free Cash Flow OCF − CapEx | $-78.36M | $-60.80M | $-41.16M | $-71.41M |
Shares Outstanding | 15.49M | 14.78M | 14.27M | 14.85M |
No sell-side coverage available for NGNE.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for NGNE.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.